Volpara Health Technologies Ltd traded at 0.62 this Friday December 9th, decreasing 0.01 or 1.60 percent since the previous trading session. Looking back, over the last four weeks, Volpara Health Technologies Ltd lost 5.38 percent. Over the last 12 months, its price fell by 43.06 percent. Looking ahead, we forecast Volpara Health Technologies Ltd to be priced at 0.61 by the end of this quarter and at 0.57 in one year, according to Trading Economics global macro models projections and analysts expectations.

Stock Price
0.62
Daily Change
-1.60%
Yearly
-43.06%

Ok
Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
width
height
Peers Price Day Year
Alcidion Group Ltd 0.15 -0.01 -3.23% -42.31%
Nanosonics Ltd 4.84 0.09 1.89% -16.98%
PainChek Ltd 0.04 -0.001 -2.70% -36.84%
Pro Medicus Ltd 58.79 0.32 0.55% 0.20%
Polynovo Ltd 1.95 0.01 0.52% 41.45%


Volpara Health Technologies Ltd
Volpara Health Technologies Limited is a New Zealand-based research, development, and manufacturing company that provides breast imaging analytics and analysis products. The Company is engaged in developing digital health solutions to enable personalized breast cancer screening based on objective measurements of breast density, compression, and radiation dose. Its geographic segments include North America, Europe, the Middle East and Africa (EMEA), Asia-Pacific (APAC), and Corporate. The Company's offerings include VolparaEnterprise, which enables breast imaging providers to perform control checks; VolparaDensity, which provides objective assessment of a woman's breast density; VolparaRisk is a software that features a patient questionnaire; VolparaLive provides technologists with real-time decision support at the point of care to assess image quality, and Aspen Brest, which is a workflow software that optimizes operations and administration for breast cancer screening programs.